P4–278: Clinical gamma‐secretase inhibitors (GSIs) alter beta‐amyloid 40/42 ratio in brain and show CSF beta‐amyloid rebound <i>in vivo</i>
Charles E. Nolan(Pfizer (United States)), David Riddell(Eli Lilly (United States)), Cathleen Gonzales, Antonia F. Stepan(Pfizer (United States)), Stephen Noell(Pfizer (United States)), Claude Ambroise(Pfizer (United States)), Leslie R. Pustilnik(Pfizer (United States)), Chakrapani Subramanyam(Pfizer (United States)), Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ashley Robshaw(Pfizer (United States)), Christine Oborski(ProterixBio (United States)), Liming Zhang(Peking University), Ivan Efremov(Pfizer (United States)), Éva Hajós‐Korcsok(Pfizer (United States)), Yasong Lu(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
|Nature Medicine|2012|634
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351